肝纤维化的发病机制及治疗新靶点

近年来,肝纤维化的基础研究进展非常迅速。简单回顾了肝纤维化的细胞和分子发病机制,主要包括肌成纤维细胞的来源、免疫调节、自噬、表观调节。同时简要介绍了肝纤维化的几种治疗策略,为肝纤维化的治疗提供新的治疗靶点,分析表明祛除病因是目前最重要的抗肝纤维化治疗方法。尽管目前已经出现了针对不同靶点的抗纤维化药物,但大多数还处于早期研发阶段,尚需经过严格的临床研究才能确认其疗效。...

Full description

Saved in:
Bibliographic Details
Published in临床肝胆病杂志 Vol. 33; no. 3; pp. 409 - 412
Main Author 张伟 贾继东
Format Journal Article
LanguageChinese
Published 首都医科大学附属北京友谊医院肝病中心,北京,100050 2017
Subjects
治疗
肝硬化
述评
editorial
治疗
述评
肝硬化
therapy
liver cirrhosis
Online AccessGet full text

Cover

More Information
Summary:近年来,肝纤维化的基础研究进展非常迅速。简单回顾了肝纤维化的细胞和分子发病机制,主要包括肌成纤维细胞的来源、免疫调节、自噬、表观调节。同时简要介绍了肝纤维化的几种治疗策略,为肝纤维化的治疗提供新的治疗靶点,分析表明祛除病因是目前最重要的抗肝纤维化治疗方法。尽管目前已经出现了针对不同靶点的抗纤维化药物,但大多数还处于早期研发阶段,尚需经过严格的临床研究才能确认其疗效。
Bibliography:ZHANG Wei, JIA Jidong. （Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China）
In recent years,the basic research on liver fibrosis has been progressed rapidly.This article briefly reviews the cellular and molecular mechanisms of liver fibrosis,including the origin of myofibroblasts,immune regulation,autophagy,and epigenetic regulation,and introduces several new therapeutic targets.More and more evidences show that successful removal of causes is the most important antifibrotic therapy.At present,although the antifibrotic drugs acting on different targets have been emerging,most of them are still in the early stage of research and development,and well-designed clinical trials are needed to confirm their clinical efficacy.
liver cirrhosis; therapy; editorial
22-1108/R
ISSN:1001-5256
DOI:10.3969/j.issn.1001-5256.2017.03.001